Eribulin in metastatic breast cancer: Real world data

CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.PMID:38073367 | DOI:10.3233/BD-230031

Source: Breast Disease - December 11, 2023 Category: Cancer & Oncology Authors: Clara Luz Fern ández-Laguna Ivan Maray Lola Macia-Rivas Cristina Álvarez-Asteinza Sergio Fern ández-Lastras Veronica Velasco Dur ántez M ónica Carbajales Álvarez Ana Lozan-Bl ázquez Source Type: research